<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="epidemic50noCov/PMC6961731/results/search/inn/results.xml">
  <result pre="a placebo-controlled US–French protocol to prevent transmission during pregnancy by" exact="zidovudine" post="(ACTG076-ANRS024) provided the first stunning success of antiretroviral therapy:"/>
  <result pre="(ACTG076-ANRS024) provided the first stunning success of antiretroviral therapy: oral" exact="zidovudine" post="administered prepartum, intravenously during labor, and then postpartum in"/>
  <result pre="are still limited or virtually zero. The recent warning about" exact="dolutegravir" post="(see below), the latest generation molecule, calls for caution"/>
  <result pre="uncontrolled viral replication at delivery (high risk of transmission)h. aABC:" exact="abacavir" post="+ 3TC: lamivudine or TDF: tenofovir + FTC: emtricitabine."/>
  <result pre="at delivery (high risk of transmission)h. aABC: abacavir + 3TC:" exact="lamivudine" post="or TDF: tenofovir + FTC: emtricitabine. brDRV: darunavir or"/>
  <result pre="risk of transmission)h. aABC: abacavir + 3TC: lamivudine or TDF:" exact="tenofovir" post="+ FTC: emtricitabine. brDRV: darunavir or rATZ: atazanavir, both"/>
  <result pre="+ 3TC: lamivudine or TDF: tenofovir + FTC: emtricitabine. brDRV:" exact="darunavir" post="or rATZ: atazanavir, both boosted by ritonavir. cRTG: raltegravir"/>
  <result pre="brDRV: darunavir or rATZ: atazanavir, both boosted by ritonavir. cRTG:" exact="raltegravir" post="or DTG: dolutegravir (DTG is contraindicated during the first"/>
  <result pre="rATZ: atazanavir, both boosted by ritonavir. cRTG: raltegravir or DTG:" exact="dolutegravir" post="(DTG is contraindicated during the first trimester of pregnancy)."/>
  <result pre="(DTG is contraindicated during the first trimester of pregnancy). dEFZ:" exact="efavirenz" post="or NVP: nevirapine. eIntravenous perfusion of AZT: zidovudine. fAZT"/>
  <result pre="eIntravenous perfusion of AZT: zidovudine. fAZT zidovudine. gNVP nevirapine. hAZT" exact="zidovudine" post="+ NVP nevirapine. Expert advice for triple therapy or"/>
  <result pre="of minimal severity – has been observed after exposure to" exact="zidovudine" post="[40]. More recently, an alert has suggested possible neural-tube"/>
  <result pre="as mitochondrial dysfunction observed after exposure to zidovudine, didanosine, and" exact="stavudine" post="(± lamivudine). Although such disturbances are most often asymptomatic,"/>
  <result pre="increased risk of cancer associated with in utero exposure to" exact="didanosine" post="was thus demonstrated several years after its use by"/>
  <result pre="to HIV-positive mothers and a national cancer registry [45]. Fortunately," exact="didanosine" post="– a genotoxic nucleoside analog – was very little"/>
  <result pre="of maternal-infant transmission of human immunodeficiency virus type 1 with" exact="zidovudine" post="treatment. Paediatric AIDS Clinical Trials Group Protocol 076 study"/>
  <result pre="in pregnancy. Lancet HIV. 2018;5:e457–e467.29958853 [23]ZashR, MakhemaJ, ShapiroRLNeural-tube defects with" exact="dolutegravir" post="treatment from the time of conception. N Engl J"/>
  <result pre="GoujonS, DelteilC, et alRisk of cancer in children exposed to" exact="didanosine" post="in utero. AIDS. 2016;30:1245–1256.26854809 [46]André-SchmutzI, Dal-CortivoL, SixE, et alGenotoxic"/>
 </snippets>
</snippetsTree>
